GSS

GENETICSIG FPO [GSS]
Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. It offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, and Rubella detection kits under the EasyScreen name. The company was incorporated in 2001 and is headquartered in Newtown, Australia.
Healthcare · ASX Small Cap
$0.0630 -1.6%

Updated 14 Jul 2026 · Signals refresh every scan

Get alerts when GSS triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track GSS — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
  • Strong cash runway (12 quarters)
  • Low P/S ratio (0.7x)
  • EPS estimates revised downward (-10pts)
  • Near 52-week low (2% of range)
  • Micro-cap ($5-20M) - high risk
  • New substantial holder(s) (1)
  • Substantial holder(s) ceased (1)
  • CANSLIM I: Institutional ownership (53%)
  • Sentiment is mixed — no strong consensus either way
  • This one has been in freefall — down 75% over the past year
  • RBA hiking (-3pts)
  • Calendar: Quarterly 4C in 7d (+5pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Deeply negative margins (-57%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • The bigger volume days are the down days — volume-weighted momentum is negative (-3.52%/day)
Ask Scout AI about GSS
"What's driving GSS today?" "How does GSS compare to peers?" "Key risks for GSS?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

HIGH Becoming a substantial holder from BDX
HIGH Ceasing to be a substantial holder
NONE GSS responds to the BCAL Diagnostics Announcement
NONE BCAL to Acquire Shares in Genetic Signatures
NONE Change of Company Secretary

Recent ASX Announcements

2026-07-02 Becoming a substantial holder from BDX
2026-07-02 GSS responds to the BCAL Diagnostics Announcement PRICE SENSITIVE
2026-07-02 BCAL to Acquire Shares in Genetic Signatures PRICE SENSITIVE
2026-07-01 Ceasing to be a substantial holder
2026-06-18 Change of Company Secretary

Key Metrics

$14.5M
Market Cap
877K
Avg Volume
0.3x
Vol Ratio
$0.06 — $0.43
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-22.8%
ROE
-56.5%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 67%
LLeader vs LaggardlaggardRS: -34
IInstitutional SponsorshippassInst: 53%
MMarket DirectionneutralNeutral

Sector: Healthcare

109 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
ECS -20.0%MEM -12.5%NTI +12.5%VBS +11.4%BDX +11.0%
Compare:GSS vs ECSGSS vs MEMGSS vs NTI
Scout Pro — Deeper Analysis for GSS
Try Pro free for 30 days
Share this analysis

Track GSS and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required